This is a working overview of NAD+, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-05 and is reviewed periodically as new material appears.
Dietary sources of NMN include small amounts in certain vegetables, fruits, and other foods, although exact values vary by sample and method. Endogenous NMN concentrations are tightly regulated and often low, making measurement in blood or tissues technically demanding. After oral intake, NMN is thought to be rapidly metabolized in the intestine and liver, and intact NMN may not reach all tissues at high levels. Some rodent studies report increases in tissue NAD+ after oral NMN, while human data remain limited and sometimes rely on blood NAD+ metabolites rather than direct tissue measures.
Research on NMN has focused on aging, metabolic regulation, exercise capacity, and insulin sensitivity, but findings are preliminary. Many human trials are small, short in duration, and use different endpoints, which complicates comparison across studies. No national regulator has approved NMN as a therapeutic drug for any indication. In some countries it is sold as a supplement or research chemical, while other jurisdictions have questioned its status under food or supplement laws. Claims about extending human lifespan or reversing aging are not supported by established clinical evidence.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms, including bacteria, plants, and mammals. Its structure consists of a nicotinamide ring attached to a ribose-phosphate group. NMN functions as an intermediate in the NAD+ salvage pathway, a recycling route that regenerates nicotinamide adenine dinucleotide. The enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+.
Research interest in NMN increased after animal studies reported that oral or injected NMN can raise NAD+ levels in some tissues. How NMN is absorbed and distributed in humans is not fully established. Some evidence suggests extracellular NMN may be dephosphorylated to nicotinamide riboside before cellular uptake, while other studies propose specific transport routes. Direct human data on these mechanisms remain limited. Regulatory status also varies: in some countries NMN is treated as a dietary supplement, while elsewhere it is restricted or requires approval, and these differences affect labeling, sale, and research.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide found in the cells of many organisms. Its structure consists of a nicotinamide group linked to a ribose sugar that carries a phosphate group. NMN is an intermediate in the biosynthesis of nicotinamide adenine dinucleotide, or NAD+, a coenzyme involved in many metabolic reactions. The abbreviation usually refers to the beta anomer, though related forms can exist. In scientific literature, NMN is distinct from nicotinamide riboside, another NAD+ precursor.
| Property | Value | Notes |
|---|---|---|
| Chemical name | Nicotinamide mononucleotide | Nucleotide intermediate in NAD+ salvage pathway |
| Common abbreviation | NMN | Also written as β-NMN |
| Molecular formula | C11H15N2O8P | Uncharged parent form |
| Molar mass | 334.22 g/mol | Calculated from formula |
| CAS Registry Number | 1094-61-7 | For β-nicotinamide mononucleotide |
NAD+ serves as a coenzyme in redox reactions and as a substrate for enzymes involved in DNA repair and cellular signaling. In the salvage pathway, nicotinamide is converted to NMN by the enzyme NAMPT. NMN is then converted to NAD+ by NMNAT enzymes. A separate route links nicotinamide riboside to NMN through phosphorylation. These pathways maintain NAD+ levels, which can decline with age or metabolic stress in some tissues. The relative contribution of circulating NMN to tissue NAD+ remains an active area of study.
Research on NMN includes cell studies, animal experiments, and a growing number of human trials. Many early findings come from mice, where changes in NAD+ levels and metabolic markers have been reported. Human data are more limited, and questions remain about effective routes of administration, tissue distribution, and long-term effects. Some trials measure NAD+ in blood or tissue, while others assess physical function or metabolic outcomes. Regulatory status differs between countries, and NMN is not universally approved as a dietary supplement or therapeutic agent.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a naturally occurring nucleotide. Its structure consists of a nicotinamide ring attached to a ribose sugar that carries a phosphate group. The molecular formula is C11H15N2O8P, and the molar mass is about 334.22 grams per mole. In cells, NMN is an intermediate in the salvage pathway that recycles nicotinamide to maintain NAD+ levels. It is not the same compound as NAD+, although it is a direct precursor in one enzymatic step.
Inside cells, the enzyme nicotinamide phosphoribosyltransferase, or NAMPT, converts nicotinamide and a ribose-phosphate donor into NMN. A second enzyme, NMN adenylyltransferase, then converts NMN into NAD+. NAD+ participates in redox reactions and serves as a substrate for signaling enzymes such as sirtuins, PARPs, and CD38. Because NAD+ levels tend to decline with age in many organisms, NMN has drawn interest as a possible way to influence that decline. Whether oral NMN reliably raises NAD+ in human tissues, and whether any such change modifies disease risk, remain open research questions.
In the canonical salvage pathway, nicotinamide phosphoribosyltransferase, known as NAMPT, transfers a phosphoribosyl group to nicotinamide and releases NMN. A second enzyme, NMN adenylyltransferase, then attaches an adenylyl group to NMN to form NAD+. Alternative routes exist, including a pathway that uses nicotinamide riboside and its phosphorylated forms. The relative contribution of extracellular NMN to intracellular NAD+ pools remains an area of active investigation, and the roles of specific transporters and enzymes are not completely defined.
NMN is present in small amounts in various foods, including certain vegetables, fruits, and milk, though dietary quantities are generally low. Laboratory research often uses synthetic or enzymatically produced NMN. The compound has drawn interest because NAD+ levels decline with age in some tissues and because restoring NAD+ may affect metabolism in animal models. Whether oral NMN produces meaningful NAD+ increases in humans and whether such changes translate into health benefits are not fully established.
Nicotinamide mononucleotide, abbreviated NMN, is a naturally occurring nucleotide. Its structure combines a nicotinamide base with a ribose sugar and a phosphate group. Within cells, NMN sits on the biosynthetic route that recycles nicotinamide back into nicotinamide adenine dinucleotide, or NAD+. Because NAD+ participates in redox reactions and signaling, enzymes that produce and consume it influence many metabolic processes. The compound is therefore best described as an intermediate rather than a final signaling molecule.
Nicotinamide mononucleotide, commonly abbreviated NMN, is a pyridine nucleotide that consists of a nicotinamide ring, a ribose sugar, and a phosphate group. It is an intermediate in the salvage pathway for nicotinamide adenine dinucleotide, or NAD+, synthesis. In mammalian cells, the enzyme nicotinamide phosphoribosyltransferase produces NMN from nicotinamide and phosphoribosyl pyrophosphate. Nicotinamide mononucleotide adenylyltransferases then convert NMN into NAD+. The core structure and enzymatic route are well established in biochemical literature.
The biologically relevant form of NMN is generally the beta anomer, which is recognized by NMN adenylyltransferases. NMN is polar and water soluble, and it does not readily diffuse across lipid membranes without assistance. Whether intact NMN enters cells through a specific transporter remains an open question; some studies propose solute carrier family members, while other work favors extracellular dephosphorylation to nicotinamide riboside followed by uptake. This transport and compartmentalization debate affects how researchers interpret oral administration studies. The distinction between intracellular synthesis and extracellular delivery is central to current discussion.
Terminology around NMN can be confusing because several related compounds share the vitamin B3 family. Nicotinamide riboside is a nucleoside, whereas NMN is a nucleotide with a phosphate group, and NAD+ is a dinucleotide coenzyme rather than a simple precursor. Niacin and nicotinamide are also NAD+ precursors but follow different metabolic entry points. In commercial and scientific writing, NMN usually refers to beta-nicotinamide mononucleotide unless another form is specified. Consistent nomenclature helps distinguish chemical identity from proposed biological effects.
== Pharmacology == Dihydrocodeine exerts its analgesic action through affinity to predominantly μ-opioid receptor and to lesser extent to κ-opioid receptor and δ-opioid receptor. A 1956 source states that 30 mg of subcutaneous dihydrocodeine is equianalgesic to 10 mg of morphine. Another source states that dihydrocodeine is twice as strong as codeine and the metabolite dihydromorphine is likewise twice as strong as morphine. Dihydrocodeine (DHC) is O-demethylated into dihydromorphine (DHM) by CYP2D6 and N-demethylated into nordihydrocodeine (NDHC) by CYP3A4, summarily yielding nordihydromorphine (NDHM). Dihydrocodeine and its metabolites form 3- and 6-glucuronides. Due to the multidirectional metabolism, as opposed to tramadol and codeine, CYP2D6 activity probably does not influence DHC analgesia. The analgesia is likely achieved by the action of DHC itself, as well as DHC-6-G. DHC appears not to differ between poor and extensive metabolizers in terms of its pain threshold and pupillary reaction effect in spite of major variation in DHM blood levels. DHC-6-G is half as potent as DHC. DHM and DHM-6-G display the highest affinity to μ-opioid receptors, being 70 times as potent as DHC, whereas other metabolites display lesser affinity. DHM-6-G has similar potency as DHM, while DHM-3-G is considerably weaker. Action on δ-opioid receptor is 5-50 weaker compared to μ with the exception of DHC-6-G being twice as strong as DHC. 6-glucuronides possess lesser affinity towards κ-opioid receptors, albeit the affinity of DHC is comparable to codeine, DHM and morphine.
He conceived an idea that if a molecule that could block the enzyme is discovered, it could become an immunosuppressive drug that could be used for autoimmune diseases and in organ transplantation. In 1981 he decided to go for drug discovery and approached several pharmaceutical companies, which turned him down one by one as he had no primary knowledge of drug research. However, Syntex liked his plans and asked him to join the company with his wife. He became vice president for the research. In one of their experiments the Allisons used an antibacterial compound, mycophenolate mofetil, which was abandoned in clinical use due to its adverse effects. They discovered that the compound had immunosuppressive activity. They synthesised a chemical variant for increased activity and reduced adverse effects. They subsequently demonstrated that it was useful in organ transplantation in experimental rats. After successful clinical trials, the compound was approved for use in kidney transplant by the U.S. Food and Drug Administration on 3 May 1995, and was sold under the brand name Cellcept. It was approved for use in the European Union in February 1996.
== Methods and practices == The term optical activity is derived from the interaction of chiral materials with polarized light. In a solution, the (−)-form, or levorotatory form, of an optical isomer rotates the plane of a beam of linearly polarized light counterclockwise. The (+)-form, or dextrorotatory form, of an optical isomer does the opposite. The rotation of light is measured using a polarimeter and is expressed as the optical rotation. The magnitudes of the optical rotations of both of the enantiomers are equal (but in opposite directions). Enantiomers can be separated by chiral resolution. This often involves forming crystals of a salt composed of one of the enantiomers and an acid or base from the so-called chiral pool of naturally occurring chiral compounds, such as malic acid or the amine brucine. Some racemic mixtures spontaneously crystallize into right-handed and left-handed crystals that can be separated by hand. Louis Pasteur used this method to separate left-handed and right-handed sodium ammonium tartrate crystals in 1849. Sometimes it is possible to seed a racemic solution with a right-handed and a left-handed crystal so that each will grow into a large crystal. Liquid chromatography (HPLC and TLC) may also be used as an analytical method for the direct separation of enantiomers and the control of enantiomeric purity, e.g. active pharmaceutical ingredients (APIs) which are chiral.
Germanium is a shiny grey-white solid. It has a density of 5.323 g/cm3 and is hard and brittle. It is mostly unreactive at room temperature but is slowly attacked by hot concentrated sulfuric or nitric acid. Germanium also reacts with molten caustic soda to yield sodium germanate Na2GeO3 and hydrogen gas. It melts at 938 °C. Germanium is a semiconductor with an electrical conductivity of around 2 × 10−2 S•cm−1 and a band gap of 0.67 eV. Liquid germanium is a metallic conductor, with an electrical conductivity similar to that of liquid mercury. Most of the chemistry of germanium is characteristic of a nonmetal. Whether or not germanium forms a cation is unclear, aside from the reported existence of the Ge2+ ion in a few esoteric compounds. It can form alloys with metals such as aluminium and gold. It shows fewer tendencies to anionic behaviour than ordinary nonmetals. Its solution chemistry is characterised by the formation of oxyanions. Germanium generally forms tetravalent (IV) compounds, and it can also form less stable divalent (II) compounds, in which it behaves more like a metal. Germanium analogues of all of the major types of silicates have been prepared. The metallic character of germanium is also suggested by the formation of various oxoacid salts. A phosphate [(HPO4)2Ge·H2O] and highly stable trifluoroacetate Ge(OCOCF3)4 have been described, as have Ge2(SO4)2, Ge(ClO4)4 and GeH2(C2O4)3. The oxide GeO2 is polymeric, amphoteric, and a glass former.
Cory Dell'Olio (born 8 December 1989) is an Australian rules football player who last played for the Essendon Football Club in the Australian Football League, before he was delisted at the end of the 2014 season. He was recruited with pick #29 in the 2011 Rookie Draft, having played as a small forward for the South Fremantle Football Club in the WAFL. Prior to round 4 of the 2012 AFL season he was elevated to the senior list to replace Brent Prismall who was on the long-term injury list with an ACL injury. He made his debut that weekend against Carlton, starting the game as the substitute player and replacing Michael Hurley in the third quarter. He was delisted by Essendon at the end of the 2014 season after only playing three games in 2013 and five in 2014. He returned to South Fremantle the following year. Dell'Olio, along with 33 other Essendon players, was found guilty of using a banned performance-enhancing substance, thymosin beta-4, as part of Essendon's sports supplements program during the 2012 season. He and his team-mates were initially found not guilty in March 2015 by the AFL Anti-Doping Tribunal, but a guilty verdict was returned in January 2016 after an appeal by the World Anti-Doping Agency. He was suspended for two years which, with backdating, ended in November 2016; as a result, he served approximately fourteen months of his suspension and missed the entire 2016 WAFL season.
Sources: en.wikipedia.org
malnutrition and vitamin deficiency immunodeficiency poor oral hygiene recent illness (especially acute necrotizing ulcerative gingivitis, measles, malaria, or kwashiorkor), social and environmental factors such as maternal malnutrition and closely spaced pregnancies that result in offspring with weakened immune systems In 2026 a newly discovered bacterium, Treponema A, was found in tissue samples from current sufferers of the disease as well as in historic samples. Further research is needed to establish if this could be a causative factor.
=== Antimicrobial packaging === Antimicrobial packaging is designed to inhibit pathogenic or spoilage microorganisms on a product surface or within the package environment. Antimicrobial compounds may be incorporated into films and coatings, immobilised on a package surface, released into the package headspace, or contained in pads, labels, and separate emitters. Studied agents include organic acids, plant-derived compounds, enzymes, bacteriocins, metal ions, nanoparticles, and synthetic antimicrobial substances. The performance of antimicrobial packaging depends on the target microorganism, active-agent concentration, release rate, temperature, food composition, storage period, and contact between the package and the product. Absorbent pads used with meat, poultry, seafood, and fresh produce can combine liquid absorption with antimicrobial substances or freshness indicators.
=== Casimir effect === The Casimir effect is an interaction between disjoint neutral bodies provoked by the fluctuations of the electromagnetic vacuum. Mathematically, it can be explained by considering the normal modes of electromagnetic fields, which explicitly depend on the boundary conditions on the interacting bodies' surfaces. Due to graphene's strong interaction with the electromagnetic field as a one-atom-thick material, the Casimir effect has garnered significant interest.
Picrorhiza kurroa is one of the major income generating non-timber forest products found in the Nepalese Himalayas. It is one of the oldest medicinal plants traded from the Karnali zone. Known as kutki or कुटकी in Nepali, it is a perennial herb and is used as a substitute for Indian gentian (Gentiana kurroo).
Sources: en.wikipedia.org
NMN is nicotinamide mononucleotide, a nucleotide intermediate in the NAD+ salvage pathway. Cells use it to help regenerate NAD+, a coenzyme involved in energy metabolism and cellular signaling. It is present naturally in many organisms and is also produced synthetically for research and consumer products.
NMN is the immediate precursor to NAD+ in the salvage pathway. The enzyme NMN adenylyltransferase adds an adenylate group to NMN to form NAD+. Because NAD+ levels decline with age in some tissues, researchers study whether raising NMN availability can influence NAD+ metabolism.
No. Human evidence is limited, and no regulatory agency has approved NMN for treating or preventing aging. Some trials measure NAD+ metabolites or metabolic markers, but their results do not establish a clinical benefit. Larger, longer studies with standardized endpoints are needed.
Nicotinamide mononucleotide is a nucleotide intermediate in the biosynthesis of NAD+. It consists of nicotinamide attached to a ribose phosphate unit. NMN occurs naturally in cells and is present at low levels in some foods.